United States Biotechnology & Medical Research

Metagenomi Inc (MGX)

Track

Track

Metagenomi Inc. experienced three insider trading transactions over the past ninety days, resulting in a net negative value of approximately 3,746 USD. All recorded activities involved executive sales, occurring after the most recent earnings report. The stock price has declined 8.9% during this period, reflecting broader market trends for the healthcare firm.
Ticker: MGX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Metagenomi Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.7
Irish Jian See Remarks Executive Director
Transaction date
Planned sale
Price
147.34
Quantity 15,186 -4.7%
Value US$4,542,070
3.7
Wein Matthew See Remarks Officer
Transaction date
Planned sale
Price
271.46
Quantity 59,013 +31.7%
Value US$1,450,089
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
416.12
Quantity 92,315 +28.4%
Value US$2,658,509
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
1.60
Quantity 1,581 -0.8%
Value US$2,530
2.7
Irish Jian Chief Executive Officer Executive Director
Transaction date
Sale
Price
1.60
Quantity 1,607 -0.5%
Value US$2,571
3.7
Wein Matthew See Remarks Officer
Transaction date
Sale
Price
1.60
Quantity 482 -0.4%
Value US$771
2.3
Thomas Brian C. Non-Executive Director
Transaction date
Sale
Price
1.77
Quantity 3,830 -0.2%
Value US$6,786
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
1.77
Quantity 1,576 -0.8%
Value US$2,793
2.7
Irish Jian Chief Executive Officer Executive Director
Transaction date
Sale
Price
1.77
Quantity 1,602 -0.3%
Value US$2,839
3.7
Wein Matthew See Remarks Officer
Transaction date
Sale
Price
1.77
Quantity 199 -0.2%
Value US$353
1.5
Noonberg Sarah B. FORMER OFFICER Officer
Transaction date
Proposed sale
Price
1.90
Quantity 35,832
Value US$68,081
2.3
Thomas Brian C. Non-Executive Director
Transaction date
Sale
Price
1.81
Quantity 2,701 -0.1%
Value US$4,889
2.7
Irish Jian Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
1.81
Quantity 1,602 -0.5%
Value US$2,900
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
1.81
Quantity 1,576 -2.2%
Value US$2,853
3.7
Wein Matthew See Remarks Officer
Transaction date
Planned sale
Price
1.81
Quantity 199 -1.0%
Value US$360
Sebastian Bernales Affiliate
Transaction date
Proposed sale
Price
1.91
Quantity 769,845
Value US$1,470,404
3.7
Wein Matthew See Remarks Officer
Transaction date
Sale
Price
1.75
Quantity 199 -1.2%
Value US$348
2.3
Thomas Brian C. Chief Executive Officer Executive Director
Transaction date
Sale
Price
1.75
Quantity 10,785 -0.4%
Value US$18,874
1.5
Noonberg Sarah B. Chief Medical Officer Officer
Transaction date
Sale
Price
1.75
Quantity 5,239 -4.6%
Value US$9,168
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
1.75
Quantity 1,576 -2.1%
Value US$2,758
2.7
Irish Jian See Remarks Executive Director
Transaction date
Sale
Price
1.75
Quantity 6,390 -2.0%
Value US$11,182
3.7
Wein Matthew See Remarks Officer
Transaction date
Sale
Price
1.87
Quantity 930 -8.9%
Value US$1,744
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
1.87
Quantity 1,808 -2.9%
Value US$3,390
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
1.86
Quantity 1,559 -2.5%
Value US$2,900
3.5
Wapnick Pamela Chief Financial Officer Officer
Transaction date
Sale
Price
2.88
Quantity 6,265 -9.0%
Value US$18,043
2.3
Novo Holdings A/S Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 800,000 +85.2%
Value US$12,000,000
2.3
Novo Holdings A/S Large shareholder
Transaction date
Purchase
Price
10.25
Quantity 100,000 +inf%
Value US$1,025,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-10 2026-06-05 PlS Planned sale
2.7
Irish Jian

See Remarks

Executive Director
15,186 -4.7%
147.34
US$4,542,070 		15,186 -4.7% 147.34 US$4,542,070
2026-06-10 2026-06-05 PlS Planned sale
3.7
Wein Matthew

See Remarks

Officer
59,013 +31.7%
271.46
US$1,450,089 		59,013 +31.7% 271.46 US$1,450,089
2026-06-10 2026-06-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
92,315 +28.4%
416.12
US$2,658,509 		92,315 +28.4% 416.12 US$2,658,509
2026-03-09 2026-03-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
1,581 -0.8%
1.60
US$2,530 		1,581 -0.8% 1.60 US$2,530
2026-03-09 2026-03-05 S Sale
2.7
Irish Jian

Chief Executive Officer

Executive Director
1,607 -0.5%
1.60
US$2,571 		1,607 -0.5% 1.60 US$2,571
2026-03-09 2026-03-05 S Sale
3.7
Wein Matthew

See Remarks

Officer
482 -0.4%
1.60
US$771 		482 -0.4% 1.60 US$771
2025-12-08 2025-12-05 S Sale
2.3
Thomas Brian C.
Non-Executive Director
3,830 -0.2%
1.77
US$6,786 		3,830 -0.2% 1.77 US$6,786
2025-12-08 2025-12-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
1,576 -0.8%
1.77
US$2,793 		1,576 -0.8% 1.77 US$2,793
2025-12-08 2025-12-05 S Sale
2.7
Irish Jian

Chief Executive Officer

Executive Director
1,602 -0.3%
1.77
US$2,839 		1,602 -0.3% 1.77 US$2,839
2025-12-08 2025-12-05 S Sale
3.7
Wein Matthew

See Remarks

Officer
199 -0.2%
1.77
US$353 		199 -0.2% 1.77 US$353
2025-09-11 2025-09-11 PrS Proposed sale
1.5
Noonberg Sarah B.

FORMER OFFICER

Officer
35,832
1.90
US$68,081 		35,832 1.90 US$68,081
2025-12-01 2025-09-05 S Sale
2.3
Thomas Brian C.
Non-Executive Director
2,701 -0.1%
1.81
US$4,889 		2,701 -0.1% 1.81 US$4,889
2025-12-01 2025-09-05 PlS Planned sale
2.7
Irish Jian

Chief Executive Officer

Executive Director
1,602 -0.5%
1.81
US$2,900 		1,602 -0.5% 1.81 US$2,900
2025-12-01 2025-09-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
1,576 -2.2%
1.81
US$2,853 		1,576 -2.2% 1.81 US$2,853
2025-12-01 2025-09-05 PlS Planned sale
3.7
Wein Matthew

See Remarks

Officer
199 -1.0%
1.81
US$360 		199 -1.0% 1.81 US$360
2025-07-09 2025-07-09 PrS Proposed sale
Sebastian Bernales

Affiliate
769,845
1.91
US$1,470,404 		769,845 1.91 US$1,470,404
2025-06-09 2025-06-06 S Sale
3.7
Wein Matthew

See Remarks

Officer
199 -1.2%
1.75
US$348 		199 -1.2% 1.75 US$348
2025-06-09 2025-06-06 S Sale
2.3
Thomas Brian C.

Chief Executive Officer

Executive Director
10,785 -0.4%
1.75
US$18,874 		10,785 -0.4% 1.75 US$18,874
2025-06-09 2025-06-06 S Sale
1.5
Noonberg Sarah B.

Chief Medical Officer

Officer
5,239 -4.6%
1.75
US$9,168 		5,239 -4.6% 1.75 US$9,168
2025-06-09 2025-06-06 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
1,576 -2.1%
1.75
US$2,758 		1,576 -2.1% 1.75 US$2,758
2025-06-09 2025-06-06 S Sale
2.7
Irish Jian

See Remarks

Executive Director
6,390 -2.0%
1.75
US$11,182 		6,390 -2.0% 1.75 US$11,182
2025-03-07 2025-03-05 S Sale
3.7
Wein Matthew

See Remarks

Officer
930 -8.9%
1.87
US$1,744 		930 -8.9% 1.87 US$1,744
2025-03-07 2025-03-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
1,808 -2.9%
1.87
US$3,390 		1,808 -2.9% 1.87 US$3,390
2024-12-06 2024-12-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
1,559 -2.5%
1.86
US$2,900 		1,559 -2.5% 1.86 US$2,900
2024-09-06 2024-09-05 S Sale
3.5
Wapnick Pamela

Chief Financial Officer

Officer
6,265 -9.0%
2.88
US$18,043 		6,265 -9.0% 2.88 US$18,043
2024-02-15 2024-02-13 B Purchase
2.3
Novo Holdings A/S
Large shareholder
800,000 +85.2%
15.00
US$12,000,000 		800,000 +85.2% 15.00 US$12,000,000
2024-02-15 2024-02-09 B Purchase
2.3
Novo Holdings A/S
Large shareholder
100,000 +inf%
10.25
US$1,025,000 		100,000 +inf% 10.25 US$1,025,000
Explore more

More insider trading research around Metagenomi Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America